Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ribometrix, Inc.

http://www.ribometrix.com

Latest From Ribometrix, Inc.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Deals ImmunoOncology

Roche Inks RNA-Targeted Small Molecule Pact With Ribometrix

Deal snapshot: Roche’s third partnership around small molecule, RNA-targeted therapies taps Ribometrix’s three-dimensional structural analysis of RNA to find pockets amenable to small molecule drugs.

Deals Business Strategies

Vertex Inks RNA Splicing Pact With Skyhawk

In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.

Deals Companies

Deal Watch: Another Delay For Roche/Spark, While FTC Ups AbbVie/Allergan Merger Scrutiny

Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
UsernamePublicRestriction

Register